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ABSTRACT
Background  Polymorphisms of the peptidylarginine 
deiminase type 4 (PADI4) gene confer susceptibility to 
rheumatoid arthritis (RA) in East Asian people. However, 
studies in European populations have produced conﬂ  icting 
results. This study explored the association of the PADI4 
genotype with RA in a large UK Caucasian population.
Methods  The PADI4_94 (rs2240340) single nucleotide 
polymorphism (SNP) was directly genotyped in a cohort 
of unrelated UK Caucasian patients with RA (n=3732) 
and population controls (n=3039). Imputed data from 
the Wellcome Trust Case Control Consortium (WTCCC) 
was used to investigate the association of PADI4_94 with 
RA in an independent group of RA cases (n=1859) and 
controls (n=10 599). A further 56 SNPs spanning the 
PADI4 gene were investigated for association with RA 
using data from the WTCCC study.
Results  The PADI4_94 genotype was not associated 
with RA in either the present cohort or the WTCCC 
cohort. Combined analysis of all the cases of RA 
(n=5591) and controls (n=13 638) gave an overall OR 
of 1.01 (95% CI 0.96 to 1.05, p=0.72). No association 
with anti-CCP antibodies and no interaction with either 
shared epitope or PTPN22 was detected. No evidence 
for association with RA was identiﬁ  ed for any of the 
PADI4 SNPs investigated. Meta-analysis of previously 
published studies and our data conﬁ  rmed no signiﬁ  cant 
association between the PADI4_94 genotype and RA in 
people of European descent (OR 1.06, 95% CI 0.99 to 
1.13, p=0.12).
Conclusion  In the largest study performed to date, 
the PADI4 genotype was not a signiﬁ  cant risk factor for 
RA in people of European ancestry, in contrast to Asian 
populations.
INTRODUCTION
Rheumatoid arthritis (RA) is a complex auto immune 
disease in which genetic and environmental factors 
contribute to the pathogenesis. Around 60% of the 
risk of RA is genetic, a third of which is accounted 
for by HLA-DRB1.1 Numerous polymorphisms out-
side the HLA region have recently been conﬁ  rmed 
as RA susceptibility loci in Caucasians, but fewer 
have been tested across different ethnic populations 
and the question of whether racial heterogeneity 
exists—that is, whether possession of a particular 
allele may confer disease susceptibility in one eth-
nic group but not another—is contentious.2–4 The 
peptidylarginine deiminase 4 (PADI4) gene is of 
particular interest as it has been tested in Asian, 
European and North American populations and its 
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relative effect in relation to RA susceptibility across 
these groups remains controversial.5–13
The  PADI4 gene encodes the type 4 peptidyl-
arginine deiminase enzyme which catalyses the 
post-translational modiﬁ  cation of arginine to citrul-
line, generating citrullinated proteins. Antibodies to 
these peptides are highly speciﬁ  c for RA and often 
predate the development of disease, suggesting a 
critical role in the pathogenesis of RA. PADI4 there-
fore represents an attractive RA candidate gene and 
was ﬁ  rst reported to be associated with RA in a 
Japanese population in 2003.5 This association has 
been consistently replicated in East Asian popula-
tions6 11 12; however ﬁ  ndings in cohorts of European 
ancestry have been inconsistent. Studies in Spanish, 
Swedish and UK populations reported no evidence 
for association of PADI4 with RA.7 9 10 Conversely, 
PADI4 was found to be associated with RA in North 
American and German populations and two pub-
lished meta-analyses suggested that PADI4 poly-
morphisms do confer susceptibility to RA in those 
of European descent, albeit to a lesser degree than in 
Asian subjects.10 13–15 Consequently, it was hypoth-
esised that these European studies were underpow-
ered to detect a true but modest genetic effect. The 
present study was designed to address this issue by 
exploring the association between the PADI4 geno-
type and RA in a large UK population.
MATERIALS AND METHODS
Study design
The PADI4_94 single nucleotide polymorphism 
(SNP) (rs2240340) was selected for investigation 
as it has the strongest evidence for association 
with RA in Asians and Caucasians.5 12 14 15 It was 
genotyped in an independent UK Caucasian pop-
ulation of 3732 patients with RA and 3039 con-
trols (see online supplement). In addition, imputed 
genotypes for the PADI4_94 SNP were com-
pared between 1859 patients with RA and 2935 
controls from the Wellcome Trust Case Control 
Consortium (WTCCC) study.16 Where linkage dis-
equilibrium (LD) is high and conﬁ  dence scores for 
imputed genotypes exceed 95%, the accuracy of 
imputation in predicting actual genotype counts 
exceeds 98.4%.17 An expanded reference group 
of 10 599 subjects was created by using imputed 
genotype data for PADI4_94 from the four non-
autoimmune disease case subjects (hypertension, 
coronary artery disease, type 2 diabetes and bipolar 
disorder) genotyped as part of the WTCCC study 
and combining this with the genotype data from 
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the healthy controls. The data from the present cohort and the 
WTCCC study were combined to provide a robust estimate of 
effect size for this SNP in the UK population, giving a combined 
sample size of 5591 cases of RA and 13 638 controls. In addition, 
imputed genotype data for the original WTCCC cohort (1860 
cases of RA, 2938 controls) were used to investigate other SNPs 
spanning the PADI4 gene for evidence of association with RA. 
Analysis of data
Allele and genotype frequencies were compared between 
patients with RA and controls using the χ2 test for trend imple-
mented in PLINK. The threshold for signiﬁ  cance was deﬁ  ned at 
p<0.05.
Meta-analysis
Meta-analysis of the results together with previous studies 
investigating association of PADI4_94 with RA in populations 
of European ancestry was performed (see online supplement). 
A random effects model was used and between-study heteroge-
neity assessed using the Cochran Q-statistic (p<0.1 considered 
signiﬁ  cant).
Interaction analysis
Data were available for shared epitope (SE) and the PTPN22 
R620W SNP (rs2476601) in the current cohort. The risk of RA 
associated with carriage of PADI4_94, PTPN22 and SE risk 
alleles (1 or 2 copies) alone and in combination was calculated 
using logistic regression. Interaction effects were quantiﬁ  ed by 
calculating the attributable proportion,18 which assesses the 
proportion of the incidence that is due to interaction (ie, beyond 
the additive effects of each independent variant). There is evi-
dence of biological interaction if the attributable proportion is 
not equal to 0.
Power
The present cohort had >80% power to detect the published 
OR of 1.13 at the 5% signiﬁ  cance level (α=0.05) with a risk allele 
frequency of 0.42.15
RESULTS
The genotyping success rate was >97% in both cases and con-
trols. In this independent cohort of 3732 cases of RA and 3039 
controls, no signiﬁ  cant difference in PADI_94 allele or genotype 
frequencies was detected (table 1).
WTCCC cohort
Imputed minor allele frequencies for PADI_94 in the WTCCC 
cohort were similar to those previously reported in European 
populations and to those observed in the current study. No 
association between PADI4_94 genotype and RA was observed 
(table 1).
Combined analysis
Combined analysis of the current and WTCCC cohorts 
showed no evidence for association between PADI4_94 
genotype and RA. No significant heterogeneity between 
these two cohorts was detected (phet=0.43, I2=0%) and 
meta-analysis under a random effects model yielded a sim-
ilar overall OR of 1.00 (95% CI 0.95 to 1.05). There was no 
significant difference in genotype distribution between the 
WTCCC patients with non-  autoimmune disease, the original 
WTCCC controls and the current controls (p=0.20, χ2=6.0). 
Excluding the WTCCC patients with non-  autoimmune dis-
ease from the analysis did not affect the   outcome (OR 1.02 
(95% CI 0.97 to 1.08)).
Studies in Asian populations have shown that PADI4_94 
exerts an allele dose-dependent effect in RA susceptibility, with 
the greatest effect being seen when comparing minor allele 
homozygotes (2/2) with major allele homozygotes (1/1).5 12 In 
contrast, we found no evidence for association in any of the 
genotypic models tested (table 1).
Stratiﬁ  cation
Stratiﬁ  cation analysis creates more homogenous subsets of 
patients and thus may increase the power to detect associa-
tion despite loss of sample size. Phenotype data were avail-
able for a proportion of patients within the current cohort. 
Stratiﬁ  cation by autoantibody status, gender and SE revealed 
no evidence for association in any of the subgroups tested 
(table 2).
Meta-analysis
Five eligible studies investigating the PADI4_94 SNP for associa-
tion with RA in Caucasian populations were identiﬁ  ed.8–10 13 19 
Eight separate comparisons were available for the allelic model 
(minor allele 2 vs common allele 1) and seven for the genotypic 
model (1/2 vs 1/1 and 2/2 vs 1/1). No signiﬁ  cant association 
between PADI4_94 and RA was detected for any of the mod-
els tested (ﬁ  gure 1). The pooled OR for allele 2 vs allele 1 was 
1.06 (95% CI 0.99 to 1.13, p=0.12). The OR for 1/2 vs 1/1 was 
1.04 (95% CI 0.92 to 1.17, p=0.53) and for 2/2 vs 1/1 was 1.07 
(95% CI0.96 to1.19, p=0.20). Signiﬁ  cant between-study hetero-
geneity was noted (phet=0.06, I2=49.1%). Analysis restricted to 
European cohorts (ie, excluding North American cohorts whose 
genetic background may be more ethnically diverse) gave an OR 
Table 1 PADI4_94 (rs2240340) genotypes in current and WTCCC cohorts
RA cases* Controls* Allele 2 vs 
allele 1 OR 
(95% CI) p Trend
12 vs 11 OR 
(95% CI)
22 vs 11 OR 
(95% CI)   11 12 22 MAF 11 12 22 MAF
Current 
cohort
1238 (33.2) 1841 (49.3) 653 (17.5) 0.42 1018 (33.5) 1508 (49.6)   513 (16.9) 0.42 1.02 
(0.95 to 1.09)
0.58 1.00 
(0.90 to 1.12)
1.05 
(0.91 to 1.20)
WTCCC   665 (35.8)   860 (48.3) 334 (18.0) 0.41 1031 (35.1) 1434 (48.9)   470 (16.0) 0.40 1.03 
(0.95 to 1.12)
0.54 0.93 
(0.82 to 1.06)
1.10 
(0.93 to 1.30)
WTCCC 
plus non-
autoimmune 
controls
  665 (35.8)   860 (48.3) 334 (18.0) 0.41 3614 (34.1) 5154 (48.6) 1831 (17.3) 0.42 0.98 
(0.91 to 1.05)
0.59 0.91 
(0.81 to 1.01)
0.99 
(0.86 to 1.14)
Combined 
analysis
1903 (34.0) 2701 (48.3) 987 (17.7) 0.42 4632 (34.0) 6662 (48.8) 2344 (17.2) 0.42 1.01 
(0.96 to 1.05)
0.72 0.99 
(0.92 to 1.06)
1.02 
(0.94 to 1.12)
*Data shown as number (%).
1, major (common) allele; 2, minor (rare) allele; MAF, minor allele frequency; WTCCC, Wellcome Trust Case Control Consortium.
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Table 2  PADI4_94 genotype in current cohort stratiﬁ  ed by autoantibody status, carriage of SE, presence of erosions and gender
Cases* Controls*
Allele 2 vs 1 OR 
(95% CI) p Trend   11 12 22 Total 11 12 22 Total
CCP +ve vs all controls 498 (33.2) 722 (48.2) 279 (18.6) 1499 1018 (33.5)  1508 (49.6)  513 (16.9)  3039 1.04 (0.95 to 1.14) 0.36
CCP –ve vs all controls 241 (34.4) 347 (49.5) 113 (16.1) 701 1018 (33.5)  1508 (49.6)  513 (16.9)  3039 0.97 (0.86 to 1.09) 0.57
CCP +ve vs CCP –ve 498 (33.2) 722 (48.2) 279 (18.6) 1499   241 (34.4)   347 (49.5) 113 (16.1) 701 1.08 (0.95 to 1.23) 0.25
RF +ve vs all controls 849 (33.4) 1250 (49.1)  444 (17.5)  2543 1018 (33.5)  1508 (49.6)  513 (16.9)  3039 1.01 (0.94 to 1.09) 0.71
RF –ve vs all controls 328 (34.2)  467 (48.7)  165 (17.2)  960 1018 (33.5) 1508 (49.6)  513 (16.9)  3039 0.99 (0.89 to 1.10) 0.89
Erosions 394 (33.8) 576 (49.4) 195 (16.8) 1165 1018 (33.5) 1508 (49.6) 513 (16.9)  3039 0.99 (0.9 to 1.09) 0.85
No erosions 183 (33.0) 270 (48.8) 101 (18.2) 554 1018 (33.5) 1508 (49.6) 513 (16.9)  3039 1.04 (0.91 to 1.18) 0.57
SE +ve (1 or 2 copies) 747 (33.3) 1093 (48.6) 407 (18.1) 2247   214 (36.2)   276 (46.6) 102 (17.2) 592 1.08 (0.95 to 1.23) 0.24
SE –ve (0 copies) 244 (32.7) 373 (49.9) 130 (17.4) 747   231 (32.6)   359 (50.6) 119 (16.8) 709 1.01 (0.87 to 1.17) 0.88
Men 334 (32.3)  524 (50.7)  176 (17.0)  1034   304 (32.6)    471 (50.5)  158 (16.9)  933 1.01 (0.89 to 1.15) 0.91
Women 896 (33.6)  1294 (48.6)  474 (17.8)  2664  657  (33.9)   964  (49.8)  315 (16.3)  1936 1.04 (0.95 to 1.13) 0.38
*Data shown as number (%).
1, major (common) allele; 2, minor (rare) allele; RF, rheumatoid factor; SE, shared epitope.
Figure 1  Meta-analysis of PADI4_94 in populations of European descent. Odds ratio (OR), minor allele (2) vs common allele (1). Weight expressed 
as percentage.
of 1.01 (95% CI 0.96 to 1.07) with no signiﬁ  cant heterogeneity 
(phet=0.31, I2=16.8%).
Interaction analysis
Signiﬁ  cant interaction between SE and PTPN22 was detected 
in anti-CCP positive RA, consistent with previous reports 
(tables 3 and 4).20 In contrast, there was no signiﬁ  cant interac-
tion between PADI4_94 and either PTPN22 or SE. In a model 
containing all three factors, the highest ORs were seen with pos-
session of SE alleles in conjunction with the PTPN22 risk allele, 
regardless of the presence or absence of the PADI4_94 putative 
risk allele (data not shown).
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Further PADI4 SNPs
Imputed genotype data were available for 1860 cases of RA 
and 2938 controls from the WTCCC study. A further 56 SNPs 
spanning the PADI4 gene with imputation conﬁ  dence scores of 
over 99% were identiﬁ  ed. No evidence for association with RA 
was detected for any of these SNPs (see table 1 in online supple-
ment). Importantly, PADI4_89 and PADI4_90, which have previ-
ously been reported to be associated with RA in Caucasians, 
were not associated in this UK cohort (see table 2 in online 
supplement).13 21
DISCUSSION
In the largest study performed to date, we found no evidence for 
association between the PADI4_94 SNP and RA in a combined 
sample of over 19 000 UK subjects. The results were consistent 
across two large independent populations, lending weight to 
these ﬁ  ndings.
This contrasts with the convincing evidence that PADI4 is 
an RA susceptibility gene in East Asian subjects.5 6 11 12 The 
strongest association is seen with PADI4_94, with an esti-
mated OR of 1.31, making it the major genetic risk factor out-
side the HLA region in this group.12 14 15 Consistent with our 
ﬁ  ndings, several other groups have failed to ﬁ  nd an association 
between PADI4_94 and RA in populations of European ancestry. 
However, meta-analyses of published data in Caucasians dem-
onstrated evidence for association with a summary OR of 
1.13.14 15 For a study to have 80% power to detect an OR of 
1.13 at p<0.05, more than 4200 subjects would be required. All 
previous studies have been underpowered to detect an OR of 
this level, conceivably accounting for the frequent failure to rep-
licate the association. However, these meta-analyses were based 
on comparatively limited data (pooled total of 2950 RA cases 
and 2300 controls) and ﬁ  ndings may have been inﬂ  uenced by 
publication bias and heterogeneity between studies. The pre-
sent study circumvents these problems by using two indepen-
dent cohorts, each with more than 80% power to detect the 
published OR, thus minimising the chance of a type II error. 
Furthermore, there was no signiﬁ  cant difference when compar-
ing minor allele homozygotes with major allele homozygotes 
(OR 1.02), which is where the greatest effect is seen in Asian 
populations (OR 1.73).12 Our ﬁ   ndings suggest that previous 
reported associations between PADI4_94 and RA in European 
populations are false-positive results.
The differential effect of the PADI4_94 SNP in populations 
of Asian and European descent is unusual as, although the fre-
quency of complex disease-associated polymorphisms may vary 
across ethnic groups, their genetic effects are usually consistent.2 
There are several plausible explanations for this discrepancy. 
Table 4  Odds ratios for developing rheumatoid arthritis (RA) according to presence or absence of SE, PTPN22 R620W and PADI4_94 risk alleles: 
allele 2 (minor allele) vs allele 1 (common allele)
Presence of risk allele All cases   CCP positive cases  CCP negative cases  
PADI4_94 PTPN22 Case:control OR (95% CI) AP (CI) Case:control OR (95% CI) AP (CI) Case:control OR (95% CI) AP (CI)
None None 876:810 Referent 0.0 (–0.4 
to 0.4)
340:810 Referent 0.0 (–0.3 
to 0.3)
182:810 Referent 0.0 (–0.4 
to 0.4) Present  None 1771:1618 1.0 (0.9 to 1.1) 680:1618   1.0 (0.9 to 1.2) 349:1618 1.0 (0.8 to 1.2)
None Present 334:191 1.6 (1.3 to 2.0) 146:191   1.8 (1.4 to 2.3) 51:191 1.2 (0.8 to 1.7)
Present Present 679:386 1.6 (1.4 to 1.9) 300:386   1.9 (1.5 to 2.3) 102:386 1.2 (0.9 to 1.5)
PADI4_94 SE
None None 244:231 Referent 0.1 (–0.1 
to 0.3)
62:231 Referent 0.1 (–0.1 
to 0.3)
94:231 Referent 0.2 (–0.1 
to 0.5) Present None 503:478 1.0 (0.8 to 1.2) 154:478   1.2 (0.9 to 1.7) 162:478 0.8 (0.6 to 1.1)
None Present 747:214 3.3 (2.6 to 4.2) 382:214   6.7 (4.8 to 9.2) 118:214 1.4 (1.0 to 1.9)
Present Present 1500:378 3.8 (3.0 to 4.6) 747:378   7.4 (5.4 to 10.0) 240:378 1.6 (1.2 to 2.1)
PTPN22 SE
None None 553:563 Referent 0.3 (0.1 
to 0.5)
145:563 Referent 0.4 (0.1 
to 0.6)
204:563 Referent 0.2 (–0.1 
to 0.5) Present None 200:141 1.4 (1.1 to 1.8) 71:141   2.0 (0.7 to 5.7) 52:141 1.0 (0.7 to 1.5)
None Present 1610:474 3.5 (3.0 to 4.0) 779:474   6.4 (5.1 to 7.9) 270:474 1.6 (1.3 to 2.0)
Present Present 626:116 5.5 (4.4 to 6.9)   347:116 11.6 (8.8 to 15.3)   87:116 2.1 (1.5 to 2.9)  
Present, 1 or 2 copies of SE, PTPN22 R620W risk allele or PADI4_94 putative risk allele. Signiﬁ  cant results in bold.
None, no copies.
AP, attributable proportion; CCP, cyclic citrullinated peptide; SE, shared epitope.
Table 3  Details of studies included in meta-analysis and subsequent analysis of SE, PTN22 and 
PADI4_94 risk allele combinations
Study  Population
Sample size PADI4_94 allele 2 vs 1
RA cases Controls OR (95% CI) p Value
Martinez (2005)9 Spain 248 394 1.01 (0.80 to 1.26) 1.00
Harney (2005)8 UK 100 94 1.20 (0.80 to 1.80) 0.41
Plenge (2005): EIRA10 Sweden 1498 858 1.01 (0.89 to 1.14) 0.93
Plenge (2005): NARAC10 North America 895 748 1.24 (1.06 to 1.42) 0.003
Hoppe (2006)13 German 102 102 1.55 (1.05 to 2.30) 0.04
Costenbader (2008)19 North America 430 426 1.07 (0.89 to 1.30) 0.49
WTCCC UK 1859 10599 0.98 (0.91 to 1.05) 0.58
Current cohort UK 3732 3039 1.02 (0.95 to 1.09) 0.72
EIRA, Epidemiological Investigation of Rheumatoid Arthritis; NARAC, North American Rheumatoid Arthritis Consortium; SE, 
shared epitope; WTCCC, Wellcome Trust Case Control Consortium.
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First, linkage disequilibrium varies between races, so PADI4_94 
may be in linkage disequilibrium with the true disease-associ-
ated allele in Asian but not Caucasian populations. However, 
PADI4 SNP and haplotype frequencies are similar in the two 
populations.7 Second, it is possible that different PADI4 poly-
morphisms may be associated with RA in Caucasians. However, 
this would be unlikely given that we investigated numerous 
SNPs spanning the PADI4 gene within the WTCCC cohort and 
found no evidence for association across the locus as a whole. 
Third, the biological effect of PADI4_94 variants may be mod-
ulated by environmental exposures such as smoking or interac-
tions with other genes which may differ between races. The 
PTPN22 R620W variant is a potential candidate for introducing 
variation via gene–gene interaction as it is a major risk factor for 
RA in Caucasians but has not been detected in Japanese popu-
lations. However, we found no interaction between PADI4_94 
and PTPN22 in this study. Alternatively, it may be that PADI4 
is associated only with a subgroup of patients with RA. Hoppe 
et al recently suggested that the association between PADI4 
genotype and RA may be restricted to patients with more severe 
disease.22 It is unlikely, however, that this would account for 
the differences observed as the cohorts tested in the WTCCC 
and current studies were comparable with the Japanese cohort 
in terms of disease characteristics. Moreover, PADI4 genotype 
was not associated with the presence of cyclic citrullinated pep-
tide (CCP) antibody, rheumatoid factor or erosions in this study, 
and we have previously found no relationship between PADI4 
genotype and disease severity in UK patients with early inﬂ  am-
matory arthritis followed prospectively.23
Finally, the disparity in genetic effect may reﬂ  ect genuine dif-
ferences in pathogenic processes between European and Asian 
populations. The mechanism by which the PADI4 genotype 
may inﬂ   uence RA susceptibility has not yet been elucidated. 
Suzuki et al showed that the PADI4 susceptibility haplotype had 
signiﬁ  cantly increased mRNA stability compared with the non-
susceptibility haplotype. In theory this could result in increased 
PAD4 enzyme, with consequently increased protein citrullina-
tion which may break immune tolerance leading to production of 
anti-citrullinated peptide antibodies (ACPA) and disease.5 They 
went on to demonstrate an association between homozygos-
ity for the PADI4 susceptibility haplotype and the presence of 
ACPA. However, we and many others have failed to ﬁ  nd any link 
between PADI4 genotype and presence of anti-CCP antibodies, 
drawing this hypothesis into question.8 10 23–25 Furthermore, given 
that individuals carrying SE alleles may be predisposed to mount 
an immune response to citrullinated peptides, the absence of a 
signiﬁ  cant interaction between PADI4_94 and SE in this study is 
of relevance.26 We did conﬁ  rm the previously reported interaction 
between PTPN22 and SE, supporting the validity of our data.20 In 
a Korean cohort, PADI4 and SE had additive effects with regard to 
the risk of RA, although no signiﬁ  cant interaction was reported.11 
It would be interesting to investigate this further in Asian popula-
tions as distribution of HLA subtypes varies across races and it 
has been suggested that this could lead to differential modulation 
of the genetic effects of PADI4.8 11
In conclusion, in contrast to Asian populations, the PADI4 
genotype is not a signiﬁ  cant risk factor for RA in people of 
European descent. Identiﬁ   cation of biological mechanisms 
responsible for this disparity may yield novel insights into the 
pathogenic processes underpinning rheumatoid disease.
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